





Thomas Beyersdorf, Michigan President

Tracy C. Schmidt, Utah President-Elect

Daniel H. Hayes, MD, North Carolina Medical Advisor

Marlon F. Levy, MD, Texas Medical Advisor-Elect

Leslie Cortina, Florida Secretary/Treasurer

Monica Johnson-Tomanka, Oregon Member-At-Large

Joseph S. Roth, New Jersey Immediate Past-President

Paul M. Schwab, Virginia Executive Director

of graph

July 7, 2005

THIRD PARTY SUBMISSION UNDER 37 C.F.R. § 1.99

Dear Commissioner:

The Association of Organ Procurement Organizations is submitting the enclosed publication for consideration under 37 CFR 1.99 for examination in connection with the U.S. Patent Application No. 10/813,918, filed March 31, 2004 in the name of Robert Michael Kalthoff et al.

Publication for consideration:

AOPO Update, Volume 9, Number 3, April, 1994.

Pursuant to 37 C.F.R. § 1.99 and 1.17 (p), you will find the enclosed check for \$180 written out to the Commissioner for Patents.

Sincerely,

Paul M. Schwab

Executive Director

RECEIVED

JUL 1 8 2005

GROUP 3600

Enclosures

07/12/2005 SZEWDIE1 00000031 10813918

01 FC:1806

180.00 OP



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

ROBERT KALTHOFF ET AL.

: EXAMINER: TOMASZEWSKI, M.

SERIAL NO: 10/813,918

FILED: MARCH 31, 2004

: GROUP ART UNIT: 3626

FOR: SECURE NETWORK GATEWAY

FOR ACCESSIBLE PATIENT DATA

AND TRANSPLANT DONOR

DATA

CERTIFICATE OF SERVICE

This is to certify that a copy of the Third Party Submission Under 37 C.F.R. § 1.99, which is enclosed herewith, was sent via First Class U.S. Mail on July 8, 2005, to Taft, Stettinius

& Hollister LLP, Suite 1800, 425 Walnut Street, Cincinnati, OH 45202-3957.

Dated: July 8, 2005

Andrew T Harry

Registration No. 56,959

RECEIVED

JUL 1 8 2005

GROUP 3600

For the Advancement of Organ Procurement

A Report from the President Diana L. Clark

The Executive Office Decision Saga:

Late in March, I sent an update to each member OPO. Well, I am still the "acting" Executive Director.

Five Request For Proposals have been sent to association management firms. As I indicated, the firms are variable in size. To date (late April), we have received three proposals. I will be analyzing the proposals and then create a summary for the Executive Committee.

The unknown is how to provide what you, the AOPO members, want and expect at a cost that each member is willing to support. I have yet to discover quality without cost. The known is that you want a strong central influence in the transplantation community. Your Executive Committee is striving to match the known with the unknown.

I often rely on the wisdom of others; I am an avid reader and listener. Perhaps there is wisdom in some of author Warren Bennis' books:

"Whatever shape the future takes, the organizations that will succeed are those that take seriously—and sustain through action—the belief that their competitive advantage is based on the growth and development of the people in them. And the men and women who guide those organizations will be a different kind of leader than we've been used to. They will be maestros, not masters; coaches, not commanders."

This is, indeed, an important decision!

I would appreciate your taking a few minutes to write or call and provide me your concerns and suggestions about this decision, one which will greatly affect our future.

OPO Performance: The Team and the Task

There are numerous important and influential activities, projects and programs accomplished through AOPO. However, perhaps one of the most important projects

for our future is the OPO Performance Standards Task Force. This project will establish the benchmarks for our OPOs.

April 1994

Volume 9, Number 3

To assemble such a TEAM and work collaboratively with UNOS will further our collective efforts to provide leadership in the transplant community. The named leadership for the Task Force have quite a "Task" before them. There is no doubt they are up to this challenge. As we keep you up to date on activities, as we ask for information from you, and as we move quickly through this project . . . please get involved and be an integral part of the Task Force's success.

Work plans and priorities have been established for the new OPO Performance Task Force, a joint project of AOPO and UNOS. Over the next few AOPO Updates, we will look at various aspects as well as the progress of the project.

The Team:

While the scope of the project is immense, a dynamic team has been assembled and is equal to the task. Comittee Co-chairs are Rebecca Davis Standridge and Bill Pfaff, MD. Task Force members include:

OPO Executive Directors

Lori Brigham, Washington Regional
Transplant Consortium
Susan Gunderson, LifeSource
Dennis Heinrichs, LifeLink
Lloyd Jordon, Carolina Organ Procurment Agency
continues on page 2

Inside This Issue

- Eye Bank Statistics
- M AOPO Donor Form
- Committee Updates

National Organ and Tissue Donor Week New Jersey Family Honored

Newton, New Jersey resident Walter Traenkle and his wife Donna joined nearly 100 donor family members from around the nation in Washington, D.C., April 16-17, during National Organ and Tissue Donor Awareness Week (NOTDAW) to commemorate loved ones who were organ and tissue donors.

Walter Traenkle turned the tragedy of his son's death into something positive by improving the lives of others. Knowing that 40 people benefited from the tissues of his 23-year-old son prompted Traenkle to spread the word about the lifesaving possibilities of organ donation. He founded "Project Awareness" with support from his local Knights of Columbus Chapter and the statewide organization. Project Awareness, which is a program offered free of charge to community representatives, presents the facts about organ donation and transplantation and is supported by real life success stories. This program is the first of its kind in the nation, according to Traenkle.

Donor families were welcomed to Washington, D.C. on Saturday evening, April 16, with a reception and program. On Sunday, April 17, they were honored guests at the National Donor Receognition Ceremony in the Great Hall of the Hubert H. Humphrey Building, U.S. Department of Health and Human Services. Assistant Surgeon General Dr. Kenneth P. Mortsugu, a do-

nor husband, served as Master of Ceremonies. Loved ones were honored with music and remarks from donor families, transplant recipients and representatives of national transplant organizations.

1994 AOPO Donor Form is Now Available

The Special Projects Committee has now completed their revisions to the AOPO Donor Form. The form has been approved by the AOPO Executive Committee and is now available to the membership. AOPO encourages all its members to use the AOPO Donor Form. This will help in the standardization and collection of data on all donors nationwide. A copy of the form is available on diskette by submitting a written request to Mary Ellen Hanssen in the AOPO offices. Thanks to all the members of the AOPO Special Projects Committee and the 34 OPOs that provided input into the revision of this form.

PLAN TO ATTEND!

The 1994 AOPO Annual Meeting



Westin-Galleria Dallas Dallas, Texas June 8-10, 1994



AOPO

Association of

Organ Procurement

Organizations

Be an organ donor . . . it's the chance of a lifetime!™

OPO Performance continued from page 1

Rich Luskin, New England Organ Bank Ken Richardson, Kentucky Organ Donor Affiliates Paul Volek, Wisconsin Donor Network Phyllis Weber, California Transplant Donor Network

OPO Medical Directors and Transplant Surgeons
H. Keith Johnson, MD, Tennessee Donor Services
Thomas Kirby, MD, UNOS Thoracic Committee
James T. Mayes, MD, LifeBanc of Ohio,
UNOS OPO Committee
John Roberts, MD, UNOS OP&D Committee

and other individuals selected for their particluar areas of interest and expertise:

Remy Aranoff, DOT
Carol Beasley, Partnership for Organ Donation
Barbara Bernhard, OPO Finance, Indiana
Organ Procurement Organization
Sue Dunn, Hospital Development, Colorado
Organ Recovery Systems
Roger Durand, PhD, Public Policy,
University of Houston
Dennis Rager, UNOS Patient Affairs
Maureen Townsend, RN, Hartford OPO, ASMHTP

UNOS Staff
Leah Bennett
Lin McGraw
Dan Stockdreher

While this is certainly a large group, a depth and breadth of experience and disciplines is necessary to address the many facets of the project. Smaller work groups will be utilized to manage the process.

The Task:

Phase I of the project involves an analysis of various population and mortality data bases to determine the appropriate denominator for donor activity measures. Demographic variables such as age, race, sex and cause of death will also be examined. Sources of data to be utilized have been reviewed and selected and include: Census and census estimates by the Bureau of Census, mortality by multiple causes from the National Center for Health Statistics, and accident rates from the FAARS data base. A limited sample of state and OPO data was accumulated and reviewed to test assumptions and design future analyses.

Verification of OPO service areas (designated versus actual) is currently underway. For many OPO directors, this has been a real project as the project spans from 1988 to 1993. Based upon early returns of this data, there are many exceptions to HCFA designated service areas, a circumstance which must be factored into the performance standard equation. A big THANKS to all of the OPO directors and staff who turned this data request around so quickly!!!

Phase I is designed to develop OUTCOME measures. Outcome measures are the more traditional measures such as donors and organs per million, donors per hos-

pital deaths, etc. The final step of Phase I will be to merge the various population and morality date bases with service area and donor activity to determine the validity of any selected denominator and come up with either THE ANSWER(S) or more questions. Las Vegas is not posting odds at this time.

In the nest issue of AOPO Update, Phase II of the project, which includes an analysis of OPO disciplines and identification of factors which impact OPO performance will be discussed. Stay tuned.

Vitalink

VitalInk is a look into the future for procurement and transplantation. It employs technology that many in our field have scarcely heard of. This technology takes portable computing a couple of steps further.

This computer software development project is being supported by UNOS, and piloted by six OPOs nationwide. These OPOs will continue the current field tests through May, 1994. They include Indiana Organ Procurement Organization, Regional Organ Bank of Illinois, Northwest Organ Procurement Agency, Shands University Hospital at the University of Florida, Delaware Valley Transplant Program and New York Regional Transplant.

The concept allows a procurement coordinator to perform donor managements at the bedside, collecting data in an automated fashion, and transferring that data in various forms to necessary persons with just a couple of key strokes. Portable computer equipment, enhanced by pen-based technology, is the technological tool; and radio transmission is the communication mechanism.

The first phase of this project, which automates the multiple-page AOPO donor chart, was implemented in field testing in March, 1994. Fall 1994 is the target for overall implementation of this piece. Additional phases of the project will:

- (1) explore alternatives for communicating necessary donor chart data "on-line," "real time" to others in order to facilitate organ placement;
- (2) give consideration to the automation of other critical data collection forms used in our industry; and
- (3) seek ways to enhance overall data collection, data sharing and data reporting.

For additional information about this very critical project, watch future publications of this newsletter . . . "other" industry publications . . . contact David Klein or Scott Hall at UNOS.

Leadership is a verb, not a noun. Leadership is defined by what you do, not who you are. Leaders are those whom others follow.

Bill Gore, founder of W.L. Gore & Assoc.

OPO Performance continued from page 1

Rich Luskin, New England Organ Bank Ken Richardson, Kentucky Organ Donor Affiliates Paul Volek, Wisconsin Donor Network Phyllis Weber, California Transplant Donor Network

OPO Medical Directors and Transplant Surgeons
H. Keith Johnson, MD, Tennessee Donor Services
Thomas Kirby, MD, UNOS Thoracic Committee

James T. Mayes, MD, LifeBanc of Ohio, UNOS OPO Committee John Roberts, MD, UNOS OP&D Committee

and other individuals selected for their particluar areas of interest and expertise:

Remy Aranoff, DOT
Carol Beasley, Partnership for Organ Donation
Barbara Bernhard, OPO Finance, Indiana
Organ Procurement Organization
Sue Dunn, Hospital Development, Colorado
Organ Recovery Systems
Roger Durand, PhD, Public Policy,
University of Houston
Dennis Rager, UNOS Patient Affairs
Maureen Townsend, RN, Hartford OPO, ASMHTP

UNOS Staff
Leah Bennett
Lin McGraw
Dan Stockdreher

While this is certainly a large group, a depth and breadth of experience and disciplines is necessary to address the many facets of the project. Smaller work groups will be utilized to manage the process.

The Task:

Phase I of the project involves an analysis of various population and mortality data bases to determine the appropriate denominator for donor activity measures. Demographic variables such as age, race, sex and cause of death will also be examined. Sources of data to be utilized have been reviewed and selected and include: Census and census estimates by the Bureau of Census, mortality by multiple causes from the National Center for Health Statistics, and accident rates from the FAARS data base. A limited sample of state and OPO data was accumulated and reviewed to test assumptions and design future analyses.

Verification of OPO service areas (designated versus actual) is currently underway. For many OPO directors, this has been a real project as the project spans from 1988 to 1993. Based upon early returns of this data, there are many exceptions to HCFA designated service areas, a circumstance which must be factored into the performance standard equation. A big THANKS to all of the OPO directors and staff who turned this data request around so quickly!!!

Phase I is designed to develop OUTCOME measures. Outcome measures are the more traditional measures such as donors and organs per million, donors per hos-

pital deaths, etc. The final step of Phase I will be to merge the various population and morality date bases with service area and donor activity to determine the validity of any selected denominator and come up with either THE ANSWER(S) or more questions. Las Vegas is not posting odds at this time.

In the nest issue of *AOPO Update*, Phase II of the project, which includes an analysis of OPO disciplines and identification of factors which impact OPO performance will be discussed. Stay tuned.

Vitalink

VitalInk is a look into the future for procurement and transplantation. It employs technology that many in our field have scarcely heard of. This technology takes portable computing a couple of steps further.

This computer software development project is being supported by UNOS, and piloted by six OPOs nationwide. These OPOs will continue the current field tests through May, 1994. They include Indiana Organ Procurement Organization, Regional Organ Bank of Illinois, Northwest Organ Procurement Agency, Shands University Hospital at the University of Florida, Delaware Valley Transplant Program and New York Regional Transplant.

The concept allows a procurement coordinator to perform donor managements at the bedside, collecting data in an automated fashion, and transferring that data in various forms to necessary persons with just a couple of key strokes. Portable computer equipment, enhanced by pen-based technology, is the technological tool; and radio transmission is the communication mechanism.

The first phase of this project, which automates the multiple-page AOPO donor chart, was implemented in field testing in March, 1994. Fall 1994 is the target for overall implementation of this piece. Additional phases of the project will:

- (1) explore alternatives for communicating necessary donor chart data "on-line," "real time" to others in order to facilitate organ placement;
- (2) give consideration to the automation of other critical data collection forms used in our industry; and
- (3) seek ways to enhance overall data collection, data sharing and data reporting.

For additional information about this very critical project, watch future publications of this newsletter ... "other" industry publications ... contact David Klein or Scott Hall at UNOS.

Leadership is a verb, not a noun. Leadership is defined by what you do, not who you are. Leaders are those whom others follow.

Bill Gore, founder of W.L. Gore & Assoc.

Executive Director

Organ Procurement Agency Sacramento, California

A challenging position is available for a talented administrator in the emerging field of organ procurement. Responsibilities include coordinating activities, developing strategies for agency-hospital cooperation, formulating job descriptions and compensation programs, coordinating financial responsibilities and overseeing data collection. You should have hospital or related administrative experience which includes familiarity with finance and Medicare reimbursement and marketing knowledge. A nonprofit orientation, strong problem solving, strong managerial skills, and ability to resolve conflicts are essential. Experience in organ procurement field would be preferable, as would computer literacy. For this highly visible position, we offer a competitive salary and comprehensive benefits.

Please send resumé to:

Regina Workman 1600 Hayes Street, #300 Nashville, TN 37203 (615) 329-2513 (FAX) An Equal Opportunity Employer

Meetings

May 11-13, 1994
Interaction Strategies: Transplant
Coordinators as Educators Workshop
Location: Omni Netherlands Plaza,
Cincinnati, Ohio

September 14-16, 1994
Interaction Strategies: Transplant
Coordinators as Educators Workshop
Location: Sheraton Old Town Hotel,
Albuquerque, New Mexico

October 17-18, 1994
Successful Interviewing and Hiring of
Procurement Coordinators Workshop
Location: Embassy Suites, Dallas, Texas

For more information about all the workshops listed above contact:
UNOS Education Department at (804) 330-8541

Attention Recovery Coordinators

Unique Opportunity Available

Challenging position for independent, self-directed and highly motivated health care professional. Responsibilities include hands-on evaluation and management of organ and tissue donors and coordination of surgical recovery procedure. Design and implementation of educational programs are an integral part of the position. Positions available in Shreveport, Alexandria and New Orleans. Minimum experience: Two years in ICU, OR or ER.

Resumés only to:

Robert Wilson Louisiana Organ Procurement Agency, 3501 North Causeway, Suite 940 Metairie, LA 70002

Executive Director

Organ Procurement Agency Sacramento, California

A challenging position is available for a talented administrator in the emerging field of organ procurement. Responsibilities include coordinating activities, developing strategies for agency-hospital cooperation, formulating job descriptions and compensation programs, coordinating financial responsibilities and overseeing data collection. You should have hospital or related administrative experience which includes familiarity with finance and Medicare reimbursement and marketing knowledge. A nonprofit orientation, strong problem solving, strong managerial skills, and ability to resolve conflicts are essential. Experience in organ procurement field would be preferable, as would computer literacy. For this highly visible position, we offer a competitive salary and comprehensive benefits.

Please send resumé to:

Regina Workman 1600 Hayes Street, #300 Nashville, TN 37203 (615) 329-2513 (FAX) An Equal Opportunity Employer

Meetings

May 11-13, 1994
Interaction Strategies: Transplant
Coordinators as Educators Workshop
Location: Omni Netherlands Plaza,
Cincinnati, Ohio

September 14-16, 1994
Interaction Strategies: Transplant
Coordinators as Educators Workshop
Location: Sheraton Old Town Hotel,
Albuquerque, New Mexico

October 17-18, 1994
Successful Interviewing and Hiring of
Procurement Coordinators Workshop
Location: Embassy Suites, Dallas, Texas

For more information about all the workshops listed above contact:
UNOS Education Department at
(804) 330-8541

Attention Recovery Coordinators

Unique Opportunity Available

Challenging position for independent, self-directed and highly motivated health care professional. Responsibilities include hands-on evaluation and management of organ and tissue donors and coordination of surgical recovery procedure. Design and implementation of educational programs are an integral part of the position. Positions available in Shreveport, Alexandria and New Orleans. Minimum experience: Two years in ICU, OR or ER.

Resumés only to:

Robert Wilson Louisiana Organ Procurement Agency, 3501 North Causeway, Suite 940 Metairie, LA 70002

1994 U.S. Transplant Games

Spokespeople Selected for National Kidney Foundation Sports Event

The diverse worlds of sports and soap operas may not appear to have much in common, but they are about to unite in a team effort to promote a dramatic sports event that celebrates a second chance at life.

Olympic speedskater Kristen Talbot and "General Hospital" star Shell Kepler have been named National Spokespeople for the National Kidney Foundation 1994 U.S. Transplant Games. This four-day, Olympic-style athletic competition promises to be the largest-ever gathering of transplant athletes—those individuals who have received life saving organ transplants.

The biennial event, scheduled to take place August 3-7, in Atlanta, Georgia, features 13 different sports including golf, tennis, track and field, bicycling and "3 on 3" basketball. The event is expected to attract more than 1,200 participants and thousands more in family, friends, spectators and supporters.

Both Talbot and Kepler have personal reasons for lending their time and support to this event. Talbot, who donated life-saving bone marrow to her brother just weeks before competing in this year's Winter Olympics in Lillehammer, shrugs off any talk of heroism. "It was an easy decision to donate," she said. "Skating is great, but saving my brother's life is what's really important."

Kepler, who for 14 years has portrayed the bouncy Nurse, Amy, on the popular ABC-TV soap opera, nursed her brother through more than 10 years of kidney disease before their father became his donor. "I have seen first hand the life-restoring therapy of organ transplantation and want to help others experience that rebirth. I'm confident this event will increase awareness and move people to become organ donors," commented Kepler.

Both Talbot and Kepler will be appearing at Opening Ceremonies in Atlanta on August 4, as well as presenting gold, silver and bronze medals to competitors.

Stadtlanders Pharmacy, a nationwide medication delivery and insurance billing service dedicated to serving the needs of over 10,000 transplant recipients, is the primary sponsor of the National Kidney Foundation U.S. Transplant Games. Associate sponsor is Sandoz Pharmaceuticals Corporation, makers of Sandimmune[®] (cyclosporine), an anti-rejection drug that enhances long-term patient stability following transplant surgery.

The National Kidney Foundation, the nation's largest voluntary health agency dedicated to preventing, treating and curing kidney and urinary tract diseases, is equally committed to ensuring that each of the 33,000 Americans currently awaiting a life-saving transplant receives one.

Eye Bank Association of America Releases 1993 Statistics

Eye Bank Association of America (EBM) eye banking statistics for 1993 indicate that reporting eye banks provided 42,469 corneas for sight-restoring transplant operations. This represents a slight increase over last year's total of 42,377. In the U.S., eye banks provided tissue for over 40,653 corneal transplants.

The 1993 statistics show total corneal and whole eye donations of 95,595. This represents an increase in 3.6 percent over last year's reported figure of 92,256, with only 111 banks responding, down one from last year. The average increase in donations for individual eye banks was 14.1 percent, or an average of about 31 corneas per bank.

Forty-five percent or 43,123 tissue donations were used by ophthalmologists in corneal grafts and epikeratophakia surgical procedures, with hospitals as the major source. Tissue used to research eye disease and blindness totaled 39,616.

1993 Eye Banking Totals 111 Eye Banks Reporting

Donations

	1990	1991	1992	1993	
Whole Eyes Comeal Only All Donations	28,826	58,170 31,807 89,977	32,699	38,642	

Uses

	1990	1991	1992	1993	
Corneal Grafts	40,631	41,393	42,377	42,469	
Epikeratophakia		2,010		1,160	
Research/Training	38,364	40,239	34,993	39,616	
Discarded*	3,669	5,219	7,294	8.384	

*Includes eyes not used because of medical/safety reasons, such as positive tests for infectious diseases.

Number of persons on waiting lists for corneal tissue nationwide, as of December 31, 1993 is 5,829.

Annual Number of Corneal Tranplants 1980-1993				
1980	14440	1988	36900	
1981	15509	1989	38464	
1982	20119	1990	40631	
1983	21250	1991	41393	
1984	24869	1992	42377	
1986	31340	1993	42469	
1987	35390	Total	434077.	

LifeShare Inroduces a Full Service Eye Bank

LifeShare Of the Carolinas will administrate a full service eye bank, effective May 1, 1994. The operation will include the recovery, processing and distribution of donated eye tissue within the LifeShare service area.

As an independent eye bank, LifeShare will be better able to control acquisition costs, while maintaining the highest standards of tissue quality. Service will be provided on a 24-hour basis by certified eye bank technicians and professional staff. Dr. Edward K. Isbey, III, is the medical director for the eye bank in Western North Carolina. The medical director for the Charlotte area is Dr. David N. Ugland.

LifeShare, historically, has provided support for the implementation of routine requests when offered by hospitals, giving families the option to donate organs and tissues in compliance with federal and state laws. LifeShare will continue the practice of a single contact approach with bereaved families, emphasizing discretion and sensitivity.

LifeShare is a nonprofit organ and tissue procurement organization based in Charlotte North Carolina, with a satellite location in Asheville.



AOPO Local Donor Survey (By FAX Machine)

Data & Information Management Committee Theresa Daly and Howard Nathan, Survey Coordinators

March 1994 Results

Participating OPOs	. 63
Total Population Base Reported	. 235.2 million
Total Donors Recovered	. 430 (3 NHB)

		• 1	Locally Recove That Were	red	
•	 Locally 	•	Transplanted	٠٠.	
	Recovered	(*NHB)	Anywhere	(#NHB)	_
Kidneys	792	(6)	707	(4)	_
Hearts	191	n/a	187	n/a	
Livers	345	(0)	305	(0)	
Pancreas	96	n/a	86	n/a	
Ht./Lungs	9	n/a	9	n/a	
Lungs	87	n/a	65	n/a	
Total Organs	1520	n/a	1359	n/a	
Ht. Valves	63	n/a	n/a	п/а	
Pancreas Research	ı 60	n/a	n/a	n/a	

ad hoc Medical Examiner Issues Committee

Chairperson: Teresa Shafer, RN, MSN, CPTC

The AOPO report on medical examiner issues originally released in October, 1993, will be reissued to all executive and medical directors within the next two months due to changes that were made after the initial distribution. Minor changes were made in the tables reporting donor composition by OPOs. More importantly, due to varying reporting by OPOs each year, the initial calculations for percentage of organ donors that were medical examiner cases were incorrect. The corrected information will appear as follows in the final AOPO report:

Percentage of Organ Donors that were Medical Examiner Cases

1990: 62.1 1991: 62.5 1992: 61.9

(Previously reported statistics were 50.7, 50.4 and 54.0 percent, respectively.)

The Committee is in the process of developing a onepage survey to distribute to AOPO members to determine the number of medical examiner cases of potential organ donors that were denied in 1993. This will update the data gathered in the previous report and enable us to report statistics for four years, 1990-1993.

Diana Clark, President, AOPO; Lori Brigham, Executive Director of Washington Regional Transplant Consortium; and Teresa Shafer, President, NATCO were interviewed by a *Journal of the American Medical Association (JAMA)* reporter for a two-page commentary on organ release practices by medical examiners that appeared in the March 23/30, 1994 issue of *JAMA*. The title: "Can Forensic Medicine and Organ Donation Coexist for the Public Good?" The author's first question: "IS GIVING 100% too much to ask?"

Additionally, the New Jersey Sudden Infant Death Syndrome (SIDS) case in March that was denied by the medical examiner made headlines in the Philadelphia Inquirer: "At last minute, three babies are denied donor organs," with the sub-headline: "Surgeons had to turn back. The state medical examiner had just turned parents' joy to tears." The Associated Press picked up the story and newspapers throughout the country printed the story.

AOPO, NATCO, ASTS and UNOS will be meeting this spring with representatives of the National Association of Medical Examiners (NAME) to discuss the National Guidelines which were *drafted* after a September, 1993 meeting. Hopefully, the principals in this meeting will be able to work out the issue of protection of forensic evidence and recovery of organs in order that this issue not continue to be played out in the media.

	DONOR IMPRINT
Local Non Local	
Organ Referral Only Tissue Referral Only Organ & Tiss	De Referral Concented But Not Perovered Perovered
Import/Pay Back from	Telephone No.:
OPO #UNOS ID#	Med Rec#
Recovery Date / / Coordinator Name:	
DOVOD DV	ORMATION
DONOR INF	ORMATION
Donor Hospital	Provider No. Hosp. Unit
City/State	Zip Code Telephone # ()
Date/Time Admission / / : (am/pm	
Date/Time of Referral / / : (am/pm)	Referring Person
Date/Time of Arrival / (am/pm)	Attending Physician
Donor Name	Cause of Death(See Codes)
SSN DOB/_/	Mechanism of Death (See Codes)
Address State Zipcode	Circumstances of Death (See Codes)
	Brain Death Pronounced Yes No
Age Sex Ht Wt	Method(s) Used
Race Active Military Yes No Unknown	Date/Time/ _ :MD/DO
U.S. Born Not U.S. Born	Date/Time / / : MD/DO
Ethnicity How long lived in U.S yrs.	M.E./Coroner Case Yes No
☐ Hispanic U.S. Citizen ☐ Yes ☐ No	Permission for donation Tyes No Case #
Not Hispanic Origin	Restrictions/Denial reason(s)
Not Hispanic Origin	
HLA A B DR C	Name of M.E./Coroner
ni.x x b Dk C	Date/Time of Contact / / : (am/pm)
ABO Rh Sub	Autopsy Yes No
ADO Nd	Autopsy & Too & No
CONSENT IN	FORMATION
	am/pm) Request made by:
(NOK)	Relationship
Address:	NOK Telephone # (
Consent If Not requested,	Funeral Home: Consent If No, give reason code:
Organ Requested? Write reason:	Obtained? (Specify Other)
	Yes No
Liver	
Intestine Yes No	O Yes O No
Pancreas Yes No	☐ Yes ☐ No
Lung	O Yes O No
Tissue Yes No	O Yes O No
Consent for Research	,
Tissue Bank Coordinator	

Patient Name		OPO ID #
UNOS ID #		
UNOS CODES:		·
Cause of Death	Mechanism of Death	Circumstances of Death
Anoxia	Drowing	Motor Vehicle Accident
Cerebrovascular/Stroke	Seizure	Alleged Suicide
Head Trauma	Drug Intoxication	Alleged Homicide
CNS Tumor	Asphyxiation	Alleged Child Abuse
Other:	Cardiovascular	Non-Motor Vehicle Accident
	Electrical	Other:
	Gunshot Wound	
	Stab	
•	Blunt Injury	
	Suddon Infant Dooth	

Intracranial Hemorrhage/Stroke

Other:_

atient NameNOS ID #		OPO ID #	
			·
			···
			*
-			
			
lease identify any injuries fractures incisions	tattana analal ladinasa		
lease identify any injuries, fractures, incisions, i juries, arrests, OR procedures, infections, etc.))	the diagrams and describe below. Please	discuss hospital history (inclu-
Cardiac/Respiratory Arrest (downtime)			
Chest Compressions (duration)			
OR Procedures Defibrillation			
omments:			المسا
	·		
			1, 11(1)
		17/71	
			()/- () 1 1
			1/1:11/
		The last of	The Just
,		\· ;\\ '(\``(\)``\{
		(<u>Y</u>)	\{\}
		\	MM
			[4 } }
•		W W	\smile

			OPO 1	ID #	
UNOS ID #		·			
·		INITIAL PHYS	ICAL ASSESSMENT		
			Date		Time(am/pr
PULMONARY Tubes:	Endotracheal Size	☐ Tracheostomy	Left Chest	Right Ches	it
Breath Sounds:	Equal Clear	Unequal Rales left/right	Absent left/right Rhonchi left/right	☐ Wheezes	
CARDIOVASC			,		
Lines:	PA cath	CVP.	Arterial line	INTEQUMEN	
Heart Rhythm:	Regular	Irregular	—	_	n Pale Cyanotic
Heart Tones:	Normal	Murmur	Rub	☐ Warm	Cool Temp
Periph. Pulses:	Present	1234	Absent	Bruises	Lacerations
Periph. Edema:	Present	1234	Absent	☐ Tattoos	Track marks
GASTROINTES					•
DPL:	☐ Yes	□ No	Result		
Tubes:	☐ NG	Gastrostomy	Surgical drains		
Abdomen:	Incisions	Surgical scars	Other scars (describ	`	
	Soft	Firm	Non-distended	☐ Distended	
	+ bowel sds	No bowel sds			
GENITOURINA	ARY_	* <u>-</u>			
Urine Volume:	☐ <100 cc/hr	100 - 500 cc/hr	☐ > 500 cc/hr	Anuric	
Appearance:	Clear	Cloudy	Hematuria	·	
MUSCULOSKE	LETAL				
Fractures:	Closed	Compound/open	Dressings/splints	☐ Traction	None
	DX	ONOR MEDICAL & SOCIA	AL HISTORY QUESTIONN	IAIRE	
Person Interviewe	xd:		Relationship to D	occessed:	
•	₹	•	ions regarding medical/soci	al history? 🗖 Yes (□ No
Person Conductin	g Interview and Completin	ng Form: Print Name		Title	
		Signature		Date of	f Interview
Name/I.D.# *All potential do	onors must be screened	according to the USPHS co	UNOS I.D. #(if Organ urrent criteria for exclusion	Donor) of high risk dono	rs.
		eart disease, high blood press or B/P problems? If so, wha	ure, or chest pain? Poor cire t?	culation especially	Yes No Other
		f liver disease? Any history rsons diagnosed with Hepatiti	of yellow jaundice? Been to	ld they had any	Yes No Other
	ed suffer from any type o		such a Alzheimer's, seizures	, periods of	Yes No Other
Did the decess	ed have any kidney relate	d disease? Kidney stones? Fr	equent infections? Ever been	treated with	Yes No Other

kidney dialysis?

Patient Name	OPO ID #	
UNOS ID #	-	
5. Did the deceased have a history of diabetes? How many years? Rec How many years?	uired oral medication or insulin injections?	Yes No Other
6. Did the deceased have any history of digestive or intestinal problems surgery?	? Ever have bloody stools or intestinal	Yes No Other
7. Did the deceased have any history of arthritis or joint disease? History or sore joints?	ory of broken bones? Any complaints of stiff	Yes No Other
8. Did the deceased have any history of asthma, emphysema, or any lu Tuberculosis? Ever treated for TB?	ng disease? Ever have a positive skin test for	Yes No Other
9. Has the deceased been seen by a physician or hospitalized in the pas hospital?	t two years? What physician and/or what	Yes No Other
10. Has the deceased ever had cancer or received radiation therapy or d	rugs for cancer?	Yes No Other
11. Has the deceased ever had any past surgical procedures? Please nam	e them?	Yes No Other
12. Has the deceased experienced any periods of explained or unexplained	ed weight loss?	Yes No Other
13. Did the deceased ever use illegal drugs or other substances? (i.e., c	ocaine, marijuana)	Yes No Other
14. Has the deceased ever received blood transfusions or blood products	prior to this admission?	Yes No Other
15. Was the deceased ever refused as a blood donor or told not to donate	-? Why?	Yes No Other
16. Did the deceased ever receive an organ or tissue transplant? (i.e., bo	ne, comea, skin, heart kidney)	Yes No Other
17. In the past 12 months did the deceased have a tattoo, ear piercing, ac	supuncture, or accidental needle stick?	Yes No Other
18. Was the deceased vaccinated for Hepatitis B?		Yes No Other
19. In the past 4 weeks was the deceased vaccinated for any reason?		Yes No Other
20. Was the deceased ever given human growth hormone?		Yes No Other
21. What medications, if any, did the deceased take on a regular basis?		Yes No Other
22. Did the deceased use tobacco products? Cigarettes? Packs/day? For h Other tobacco products?	ow long?	Yes No Other
23. Did the deceased drink alcohol? How much? What type? For how lo	ng?	Yes No Other

Yes No Other

24. Has the deceased ever been exposed to a toxic substance? (i.e., lead, pesticides)

Patient NameOPO ID #	
UNOS ID #	
25. In the past 12 months, was the deceased diagnosed with, or treated for, syphilis or gonorrhea, or have a reactive screening test for syphilis in the absence of a negative confirmatory test?	Yes No Othe
26. Has the deceased ever been in jail? If so, how long and where?	Yes No Other
27. Has the deceased ever been in a long term care facility? If so, how long and where?	Yes No Other
28. Has the deceased ever engaged in sex for money or drugs? Did the deceased ever have sex with anyone who had?	Yes No Other
29. Male Donors: Has the deceased ever had sex with another male even one time?	Yes No Other
30. Female Donors: Has the deceased ever had sex with a male who has had sex with another male?	Yes No Other
31. Has the deceased ever used a needle to inject drugs into their veins, muscle, or under their skin for nonmedical use? Did the deceased ever have sex with anyone who had?	Yes No Other
32. Did the deceased ever have sex with a person known or suspected to have HIV infection?	Yes No Other
33. Has the deceased ever received clotting factor concentrates for hemophilia or other bleeding disorders? Did the deceased ever have sex with anyone who had?	Yes No Other
34. Was the deceased ever exposed to known or potentially HIV-infected blood through accidental needlestick or through contact with an open wound, non-intact skin, or mucous membrane in the past 12 months.	Yes No Other
ADDITIONAL COMMENTS: (please refer to question numbers where applicable)	
P	
·	
· · · · · · · · · · · · · · · · · · ·	

Patient Name	OPO ID # ·
UNOS ID #	

	LAB PROFILE														
9LAB DATA	Admit					Final	URIN	LYSIS	Initial	Final	CBC & Diff	Admit			Final
Date							Date				Date				
Time							Time				Time				
Na+ (140-160)							Color				RBC				
K+(3.5-5.5)							Appear	ance			WBC				
Cl- (96-115)	-						рН				Hgb		T		
CO³						ì	Spec. (Grav.			На				
BUN (<20)							Protein				Platelets				
Creatinine (≤1.	ກ						Glucos	3			Segs				
Glucose (65-150)						Blood				Lymphe				
Calcium (8.5-10	.5)		<u> </u>				RBC				Bands			_	
Phosphorus (1.8-2.	o /	1	1		1	1	WBC				Monos				
Bilirubin(tot/dir)							Epith.				Eos				
SGOT(AST) (0-	ю)						Casts								
SPGT (ALT) (5-3	ภ			L			Bacteria								
GGT (17-55)				L	···········										
Alb/Tot Pro							сомм	INTS or OT	HER LAB	ESULTS:					
Mg/Cholest									,						
Alk Phos (45-110)	,	1	′		′										
LDH (90-250)					<u>'</u>	,				<u>.</u>					
PT (11-15)															
PTT (24-36)	<u> </u>										 ,				
Amylase (23-851)	-														
Lipase (0-80)				_	لـــا		Creatine	Clearance:							
	SEROLOGY					-	· 				BIOLOGY			_r	
P=Positive C=Cannot Disclos	N - Negative ND-Not Done		nkowa loterminata		CUI	TURES	DATE	24	hr RLT	DAT	E 48hri	ELT .	DATE	Final Ros	ık
	Pro Trapsf.	Post			Blood										
Anti-HIV I	PNUCNDI	PN	UCND		Blood					<u> </u>					
Anti-HIV II	PNUCNDI	PN	UCND	ı	Urine	·				_					
Anti-HTLV [PNUCNDI	PN	UCND	<u> </u>	Sputtur	GM ST							_		
Anti-HTLV II	PNUCNDI	PN	UCND	<u> </u>	Sputum					<u> </u>					
RPR-VDRL	PNUCNDI	PNI	UCND	<u>'</u>	CSF						_				
Anti-CMV	PNUCNDI		U C ND	-	R. Ure										
HBaAg	PNUCNDI	-	U C ND	\dashv	L. Ure					_	<u> </u>				
Anti-HBC .	PNUCNDI		CND		Kidney	Besin				1_					
НВаАЬ	PNUCNDI		ו מא ט נ	4					- · · -						
Anti-HCV	PNUCNDI	- 	JCNDI	-	Other										
Other PNUCNDI PNUCNDI Comenta															

TV/PEEP	PiO ₂ /Rate	IICU ₃ /Sat	CO ₂ /O ₂	pII	DATE/TIME		URINE OUTPUT		IN-TAKE	TN mayer			DOPAMINE	C.0.	PA/WEDGE	CVP	KILLIM		BP		\ \	[S' D	Y:	S	T S	0	L	I(C)	>	•	P	U	LS VII	SE P.		l'attent Name
																			8	\$ =	93.	98.60	100	8	120	3	140		8		- E	<u> </u>	220		240	103 0	TIME	H.I.V.	
																		L		L	L			L	L	L					L		L	L					
														ŀ				\vdash			\vdash		\vdash										\vdash						
														Ī				F	F			L	-	-	-	H	L			F		F	-	_	_	F	П		
																Ì					L			L	Ė	L	L												
	-	\vdash				\vdash	\vdash		t	\dagger	t	\vdash		\vdash		H	╁	t	L	L		L	L	L	L												H	-	
																		H	+	+	\vdash	\vdash	\vdash	\vdash	\vdash		\vdash	-	-	-	-	\vdash	-	\vdash	-	Н			
\vdash							_	L	\vdash	\downarrow	$oldsymbol{\downarrow}$	L	\vdash			L	Ļ	F	F	F	L		_	F	L	L		F		F					F		H	4	
																		L																				1000	
																									L								L						
										Ī								H	\vdash	-	_	-	_	_		\vdash	-					-	\vdash			Н			
								ļ										Ė	F	F																			
						-	H		十	H	\dagger	\vdash		-	┝		\vdash	L																			\vdash	1	_
																		\vdash	\vdash	_	_	-	-	\vdash	H	\vdash			Н		-	-	-		H	Н			UNOS ID#
									L		-					_	L	F	F													F	F				- -	_	=
																		L	上																				
																		H					_	_		-							-			\dashv			
П																		F																		\dashv		1	
																		F																		二			
H	\dashv	\dashv	-	-	-				\vdash	\vdash	\vdash	\vdash					\vdash	上																			+		
																		H	-							_		\dashv	\dashv	\dashv	Н	_	-	Н		\dashv			
		_	4	4	_			_		L	L																	\exists								\exists	\dashv		
		ĺ						!																												コ			
		_				·												-	Н	Н		_		Н						\dashv						\exists			>
П																		F										\dashv		\exists			F			\dashv			AVERAGE TOTAL
																													\exists							\exists); ;;
H	+	\dashv	\dashv	\dashv	\dashv		-			-			-	\dashv	\dashv	÷		L											\exists							\exists	+	1	<u> </u>
																					\neg	\exists		\exists		\dashv		\dashv	-	-	\dashv				\exists	\dashv			
															_													\exists									\prod	-	

Patient	Name					OI	PO ID #		
		CS/TEMPER		· · · · · · · · · · · · · · · · · · ·					
Date/T			dmit						T
Averag									-
Heart F									
High B	/P				- 			· · · · · ·	
Duratio									†
Low B	/P								
Duratio	 n								1
CVP									
PA		•							
PAWP									
CO/CI	-								
Temp									
Inotrop	es/vasopre	ssors							
Dosage									
INTAK			<u> </u>			OUTPUT			
Date	Time	Crystalloid Amount	Colloid Amount	Total Blood Products	24 Hr. Total/ Hr. Avg.	24 Hr. Urine Output/ Hr. Avg.	Other Amt: Non-Urine Output	24 Hr. Total Urine and Non-Urine Output	Lowest U.O. per Hi & duration
	:				 				
	:								
	:			-					
	:								
	:								
escribe l		ucts (type & s	mount)						
FDS/0	THER DI	RUGS							•
		ications	Date	-/Time Started	Dos	age	Peak Dose/Durat	tion Date/	Time Stopped
				1 :					1 :
				<i>1</i> :					<i>!</i> :
				<i>1</i> :					1 :

:

:

:

:

1

1

 7

1

1

1

:

:

:

		CARDIAC D	ATA				
EKG Date / Time /							
ECHO Date / Time / : Interpretation							
CVPE/F	ВР	1	HR		Hear	t Rhythm	
Pressors Yes No Drug	Dosage		Consulting	Physician_			
ANGIOGRAPHY Date / Time /	Consulting Ph	ysician					
	1	PULMONAR	Y DATA				
Date / Time/ Interpretation/ CHEST MEASUREMENTS RIGHT LIMING LEFT LUNG Warm (AW) Warm (AW) Warm (DW) Warm (DW) WEASUREM EXTERN STETEM		1. Len 2. Len 3. Aor 4. Dia 5. Che 6. Dis 7. Tou		t Lung Lung Vidth dth ndmark LCPA pacity	Mal TLC X A VC Agr Fem TLC X A VC		x Ht. CM -9.167 Ht. CM .335 x Ht. CM -7.49 Ht. CM
RTERIAL BLOOD GASES					[1 ir	nch = 2.54	cms)
DATE/TIME pH p	CO, pO,	нсо,	OrSat	FiO ₂	Rate	ΤV	PEEP
· :							
1 :							Γ
/ : :	- 0			<u> </u>		<u> </u>	
1 :							

	INTRAOPERATIVE	MANAGEMENT		
	/ : / : / : / :	Circle Zone (EST Circle Zone (EST) (CST) (MT) (PST)) (CST) (MT) (PST)) (CST) (MT) (PST)) (CST) (MT) (PST)	
Average HR: Lov	w BP: Duration: w HR: Duration:cc/hr Last Hour Urine Output_	High HR:	Duration:	
Medications:				
Thorazine Dosage/Time Mannitol Dosage/Time Lasix Dosage/Time Solumedrol Dosage/Time Other Dosage/Time	: Vasopressor : Blood Product : Blood Product : Crystalloids 7	Drug S Drug Drug Drug Drug Ets Type/Volume Type/Volume	Dosage/Time	: : : : : : : : : : : : : : : : : : : :
Commences.				
	OR TE	AMS		
HEART		AMS RIGHT LUNG	LEFT LU	UNG
	OR TE		LEFT LU	JNG
	OR TE		OTHERS:	JNG
HEART	OR TE HEART / LUNG	RIGHT LUNG		JNG

Patient Name__

OPO ID #_

atient Name			_ 0	PO ID #					
NOS ID #			-						
Clamp Date/Time/_/_: Instru Flush Yes No Flush	Circle Zone (E.	ST)(CST)(M Val	T)(PST) Warms I	Ischemic Time U Yes	No Duration				
Storage Solution	2011110g	Bac	ktable Flush 🔲 Y	es No Volume_	En Bloc 🛘 Yes 🗖 No				
Typing Materials: Nodes	Spleen Blood C	lot L Cel	il Prep 📙 T C	Cell					
Nephrectomy Surgeon			Assistant Sur		LEFT KIDNEY				
RIGHT KIDNEY	RIGHT		. ANATOMY	LEFT	LEFT KIDINET				
	Yes No	Aortic plaq	uc	O Yes O No					
	Yes No	Arterial pla	que	Yes No	1 (x)				
	Yes No	Infarcted at	લ	Yes No					
	Yes No.	Capsule Te	ar	☐ Yes ☐ No					
	Yes No	Subcapsula	r hematoma	O Yes O No					
BIOPSY Yes No	Yes No	Cysts/disco	loration	Yes No	BIOPSY Yes No				
RIGHT KIDNEY ANATOMY					LEFT KIDNEY ANATOMY				
Txp Resrch Disc	Not Recovered		Txp Rsrch Disc Not Recovered						
Length cm	Width	cm	Length	cm	Width cm				
Artery(s) # Distance apart				Distance apart					
Aortic Cuff Yes No	a a			Yes No					
Are multiple arteries on a common	cuff? L Yes L No		Are multiple arte	ries on a common cuff?	——————————————————————————————————————				
Length cm	cm cm		Length	cm c	m cm				
Diameter mm	mm mm		Diameter	mm	mm mm				
Vein(s)# Distance apart _			Vein(s)#	Distance apart					
Full Vena Cava Yes No			Patch of Cava	Yes No					
Length cm	cm cm		Length	cm	cm cm				
Diameter mm	mm mm		Diameter	<u>mm</u>	mm mm				
Ureter Single/Double			Ureter Single/Do	ouble					
cm c	cm cm		Length	cm.	em em				
Length Abnormalities Yes No			Abnormalities	Yes No					
Surgical Damages Yes No			Surgical Damage	s O Yes O No					
Biopsy Results:			Biopsy Results:						
Comments:			Comments:						
	<u> </u>								
Recovery Coordinator			Signature of Sur	gcon					

NOS ID #				OPO ID	"	
	planted Val	ves Research Volume	Discarde	Not Recovered/ReasonStorage Solution	Voiume	
Anatomical Abnormality						
Surgical Damage	Yes O	No Comments				
Recovering Surgeon			_ Transplant	Program	Time Recovered	ime am:
LUNG DATA Transpl	lanted Rese	earch Discard	led 🗖 Not R	ecovered/ReasonStorage Solution	Volume	
Anatomical Abnormality	Yes 🖸 :	No Comments				
Surgical Damage	☐ Yes ☐ i	No Comments .				
Rt. Lung Recov Surgeon		T	ransplant Pro	gram	Time Recovered	(am/pm)
Lt. Lung Recov Surgeon		T	ransplant Pro	gram	Time Recovered	. (am bw)
PANCREAS DATA T	ransplanted .	Iset Ceils Re	esearch D	iscarded Not Recovered/Re	ason	Char 1 2 3 ·
Splenic Flush (in pan) Star	t Time	(am/pm)	Solution		Volume	Char 1 2 3 -
S.M.A. (in pan) Start Time	e:	(am/pm)	Solution		Volume	Char 1 2 3
Whole Yes No	Celiac 🗖 Yes	☐ No Spice:	n attached 🗆	Yes No Portal Vein	Yes No	
Anatomical Abnormality		No Comments				
Surgical Damage		No Comments				
Recovering Surgeon			Transplant	Program	Time Recovered	(am/pm)
				Recovered/Reason		
	:	(am/pm) :	Solution		Volume	Char 1 2 3 -
Portal Start Time Precool Time Start Time	:	(am/pm) :	Solution		Volume	Char 1 2 3 4
Backtable Flush	:	(am/pm)	Solution	· · · · · · · · · · · · · · · · · · ·	Volume	Char 1 2 3 -
Anatomical Abnormality						
Surgical Damage		lo Comments				
Biopsy	□ Yes □ N	lo Comments				
Vessels Sent						
Gall Bladder Incised		lo Comments				
Gall Bladder Flushed						
Right Hepatic Branch		lo Comments				
Recovering Surgeon			Transplant Pr	ogram	Time Recovered	· (am/pm)
TISSUE DATA		RECOV			TECHN TISSUE	
		YES	NO	EXPLANATION IF NO		
Comeas/Eyes						
Skin						
Bone/Tendon						
Saphenous Vein (indicate	O					
Heart Valve						
Other						
ecovery Conedinator:				ORA:		

Patient Name	OPO ID #
UNOS ID #	

DISPOSITION	LEFT KIDNEY	RIGHT KIDNEY	PANCREAS
Transplant Center			
Recipient Name			
Age/Sex/Race/DOB			
SSN/HIC#			
Date of Transplant/CIT			
Diabetic	,		
Transplant Number			
ABO/HLA/PRA			
Function of Organ			
Social History			
·			

DISPOSITION	LIVER	. (3)	LUNG	HEART	SMALL BOWEL
		LEFT	RIGHT		
Transplant Center			,		
Recipient Name					
Age/Sex/Race/DOB					
SSN/HIC#					
Date Of Transplant/CIT				·	
Diabetic					
Transplant Number					
ABO/HLA/PRA					
Function of Organ					
Diagnosis					
Social History					
·					

Recovery Coordinator:	
D-/WPK//MICHELLE/DONOB EDM	